Sigma-Aldrich, Axiogenesis Ink Marketing Deal for iPSC-based Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to market Axiogenesis' mouse-induced pluripotent stem cell-derived cardiomyocytes and smooth muscle cells for preclinical cardiotoxicity screening.

The Sigma Life Science business of Sigma-Aldrich will offer the products as ready-to-order cells, application-specific kits, and custom services. Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.